The present invention relates to combination treatment methods of treating a disease comprising a type II anti-CD20 antibody and an anti-CD20/anti-CD3 bispecific antibody. The present invention further relates to methods for reduction of cytokine release associated with the administration of a T-cell activating therapeutic agent.